Evidence map›Paper›PMID 27788147›Full record

ArticlePloS one2016

Exploring the Lean Phenotype of Glutathione-Depleted Mice: Thiol, Amino Acid and Fatty Acid Profiles.

Amany K Elshorbagy, Fredrik Jernerén, Cheryl L Scudamore, Fiona McMurray, Heather Cater, Tertius Hough, Roger Cox, Helga Refsum

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Significance of GSH and HRedox report : communications in free radical research · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Amany K ElshorbagyDepartment of Physiology, Faculty of Medicine, University of Alexandria, Alexandria, Egypt.
Fredrik JernerénDepartment of Pharmacology, University of Oxford, Oxford, United Kingdom.
Cheryl L ScudamoreMary Lyon Centre, MRC Harwell Institute, Harwell Campus, Oxford, United Kingdom.
Fiona McMurrayMRC Harwell Institute, Mammalian Genetics Unit, Harwell Campus, Oxford, United Kingdom.
Heather CaterMary Lyon Centre, MRC Harwell Institute, Harwell Campus, Oxford, United Kingdom.
Tertius HoughMary Lyon Centre, MRC Harwell Institute, Harwell Campus, Oxford, United Kingdom.
Roger CoxMRC Harwell Institute, Mammalian Genetics Unit, Harwell Campus, Oxford, United Kingdom.
Helga RefsumDepartment of Pharmacology, University of Oxford, Oxford, United Kingdom.
Mary Lyon Centre at MRC Harwell · GBUniversity of Oxford · GBAlexandria University · EG

Funding

Medical Research Council G0901338Medical Research Council MC_U142661184Medical Research Council MC_UP_1502/1
6 · The paper itself

Abstract

backgroundAlthough reduced glutathione (rGSH) is decreased in obese mice and humans, block of GSH synthesis by buthionine sulfoximine (BSO) results in a lean, insulin-sensitive phenotype. Data is lacking about the effect of BSO on GSH precursors, cysteine and glutamate. Plasma total cysteine (tCys) is positively associated with stearoyl-coenzyme A desaturase (SCD) activity and adiposity in humans and animal models.

objectiveTo explore the phenotype, amino acid and fatty acid profiles in BSO-treated mice.

designMale C3H/HeH mice aged 11 weeks were fed a high-fat diet with or without BSO in drinking water (30 mmol/L) for 8 weeks. Amino acid and fatty acid changes were assessed, as well as food consumption, energy expenditure, locomotor activity, body composition and liver vacuolation (steatosis).

resultsDespite higher food intake, BSO decreased particularly fat mass but also lean mass (both P<0.001), and prevented fatty liver vacuolation. Physical activity increased during the dark phase. BSO decreased plasma free fatty acids and enhanced insulin sensitivity. BSO did not alter liver rGSH, but decreased plasma total GSH (tGSH) and rGSH (by ~70%), and liver tGSH (by 82%). Glutamate accumulated in plasma and liver. Urine excretion of cysteine and its precursors was increased by BSO. tCys, rCys and cystine decreased in plasma (by 23-45%, P<0.001 for all), but were maintained in liver, at the expense of decreased taurine. Free and total plasma concentrations of the SCD products, oleic and palmitoleic acids were decreased (by 27-38%, P <0.001 for all).

conclusionCounterintuitively, block of GSH synthesis decreases circulating tCys, raising the question of whether the BSO-induced obesity-resistance is linked to cysteine depletion. Cysteine-supplementation of BSO-treated mice is warranted to dissect the effects of cysteine and GSH depletion on energy metabolism.

Indexed as

Body WeightPhenotypeAdipose TissueAmino AcidsAnimalsBody CompositionButhionine SulfoximineEatingEnergy MetabolismFatty AcidsGlutathioneInsulinLiverLocomotionMaleMiceAmino AcidsButhionine SulfoximineFatty AcidsGlutathioneInsulinSulfhydryl Compounds

Identifiers

PMID27788147
PMCPMC5082875
OpenAlexW2543633483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.